Nastech Pharma (NSTK) Director Buys 10K Shares
Nastech Pharmaceutical (Nasdaq: NSTK) Director, Gerald Stanwick, bought 10,000 shares on 5/12 at $1.14.
Shares of NSTK are trading at 52-week low levels.
Nastech Pharmaceutical Company, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on proprietary molecular biology-based nasal drug delivery technology and proprietary ribonucleic acid interference (RNAi) technology.
Shares of NSTK are trading at 52-week low levels.
Nastech Pharmaceutical Company, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on proprietary molecular biology-based nasal drug delivery technology and proprietary ribonucleic acid interference (RNAi) technology.
You May Also Be Interested In
- W&T Offshore (WTI) CEO Buys 50K Shares
- Canaccord Genuity Maintains a 'Buy' on Cogo Group (COGO); Solid Q1; CEO Proposal on Track
- Ampco-Pittsburgh (AP) Director Buys 10K Shares
Create E-mail Alert Related Categories
Insider TradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
